Search for: "United States v. Karst" Results 1 - 20 of 38
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
19 Sep 2023, 3:34 am by Kurt R. Karst
Karst —Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. [read post]
16 Jul 2018, 12:38 pm by David Strifling
In one high-profile case pending in the United States Supreme Court, the state of Mississippi claims that Memphis, Tennessee is pumping groundwater so heavily that a depression in the water table has formed and is altering the regional flow of groundwater. [read post]
17 Jul 2013, 1:34 pm by WIMS
Appealed from the United States District Court for the Southern District of Indiana, Indianapolis Division. [read post]
6 Sep 2012, 5:25 pm by FDABlog HPM
Karst –       In a decision handed down late in the day on Thursday, September 6th, Judge Amy Berman Jackson of the U.S. [read post]
29 Aug 2012, 10:09 pm by FDABlog HPM
Karst –       It seems that hardly a day goes by without something new happening concerning patent settlement agreements. [read post]
7 Aug 2012, 7:43 pm by FDABlog HPM
Karst –       We were eager to delve into the Federal Circuit’s recent 2-1 decision in Momenta Pharmaceuticals, Inc. v. [read post]
30 Apr 2012, 7:54 pm by FDABlog HPM
”  Moreover, noted the Court, “Congress has given the United States Court of Appeals for the Federal Circuit exclusive appellate jurisdiction over patent cases. . . . [read post]
26 Sep 2011, 12:30 pm by FDABlog HPM
—The amendment made by subsection (a) shall apply to any application for extension of a patent term under section 156 of title 35, United States  Code, that is pending on, that is filed after, or as to which a decision regarding the application is subject to judicial review on, the date of the enactment of this Act. [read post]
21 Mar 2011, 1:12 pm by FDABlog HPM
  Specifically, the bill states that “[i]f the Secretary requires sponsors seeking a [PRV] to demonstrate a good faith intent to market the rare pediatric disease product in the United States, the Secretary shall first issue a guidance document setting forth the required evidentiary support necessary to demonstrate such a good faith intent. [read post]